The goal is the development of a Multimodal Innovative THeranostic nanoSystem (MITHoS) capable of covering the gap between the present anticancer nanomedicine tools and the clinical requirements. MITHoS is a hybrid theranostic nanosystem: an ultra-sound responsive core-shell nanoparticle, coupled to a pharmaceutically-relevant anticancer cargo, embedded in a cell-derived lipid bilayer shell, and finally equipped by targeting ligands. MITHoS will be validated against multiple myeloma. Cutting-edge molecular simulation techniques will be used to characterize all the involved nano/biointerfaces and develop predictive computational tools for driving the experimental investigations. The experimental synthesis, characterization, and test of the MITHoS nanosystem will evolve from simple model systems to more complex nanostructures towards the final goal of in-vivo device testing.